(►Table 2). Ovarian aging refers to the process of oocyte attrition over female reproductive life. Some but not all chemotherapies can accelerate oocyte attrition, leading to infertility and early menopause.
2 Oocytes are also sensitive to radiation, incurring dose-dependent risks of ovarian failure following radiotherapy. 3 While endocrine therapy including tamoxifen, aromatase inhibitors, and gonadotropinreleasing hormone (GnRH) agonists does not directly incur oocyte attrition, natural ovarian aging occurs concomitantly during extended time on treatment. 4 Targeted cancer therapies block cancer growth by interfering with specific molecules; in contrast to chemotherapy and radiation, there is a relative paucity of data on the impact of these treatments on fertility. 5 Of note, the Food and Drug Administration changed the content of Pregnancy and Lactation Labeling Rule in 2015
to require drug labeling information on risk to fertility for all prescription drugs submitted after June 2015; drugs approved between 2001 and 2015 will be gradually phased in. Hence, more data on fertility risk in novel agents will be reported and aid health care providers in counseling patients.
Following cancer treatment, reproductive-aged survivors are less likely to have live births than their siblings or the general population. Population-based studies in Canada, Norway, Finland, and the United States have reported lower proportions of survivors achieving births compared with controls, although there is considerable variability in how much lower these birth rates are after cancer. 6 A total of 1,194 Canadian survivors who were diagnosed as young adults subsequently had a cumulative 10-year live birth Counseling Young Female Cancer Survivors on Reproductive Health Shliakhtsitsava et al. 379
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rate of 36% compared with 40% in the control group (p < 0.001). 7 In contrast, a Norwegian study reported 13% of 16,000 cancer survivors achieved a post-cancer pregnancy following a median observation time of 5 years, compared with 22% of 80,000 controls (p < 0.001). 
10
Infertility rates are also higher in cancer survivors compared with controls, but with more limited data. In the Childhood Cancer Survivors Study, among 3,058 survivors queried at a median age of 27, 16% reported no pregnancy following !12 months of attempts or ovarian insufficiency, compared with 11% of siblings (RR: 1.5, 95% CI: 1.3-1.8).
11
Accordingly, time to pregnancy was significantly longer in survivors compared with siblings (p ¼ 0.03). In a cohort of survivors recruited from the Ontario Cancer Registry, similar proportions reported clinical infertility (15%) or being told of a fertility problem (18%), but no controls were included.
11,12
Infertility risk differed by cancer types and treatments. Uterine radiation and alkylating chemotherapy exposures are risk factors for longer time to pregnancy and/or infertility. In the Childhood Cancer Survivor Study, uterine radiation exposure of greater than 5 Gy increased the risk of infertility by 2-to 2.5-fold. 11 The highest tertile in alkylating chemotherapy exposure increased the risk of infertility by 1.5-fold (95% CI: 1.1-2.0) compared with no alkylating chemotherapy exposure. 11 Brain or head radiation was not associated with increased infertility. Because large-scale data that assess infertility are limited and infertility risk is related not only to cancer treatment exposures but also to age at pregnancy attempt, there are no current tools to predict when infertility will occur in cancer survivors.
The Fertility Window after Cancer Treatment
To prevent infertility, there are standard of care and experimental fertility preservation options that can be considered prior to starting cancer treatment. Accordingly, fertility risk counseling and referral to fertility preservation services prior to the start of cancer treatment have been recommended by the American Society of Clinical Oncology, American Academy of Pediatrics, and American Society of Reproductive Medicine.
13-15
Posttreatment, survivors frequently raise the question of whether they are fertile, if fertility may be measured, and if there is still an opportunity for fertility preservation. In women without a history of cancer, ovarian reserve biomarkers such as anti-mullerian hormone (AMH), follicle-stimulating hormone (FSH), and antral follicle count (AFC) have been associated with reproductive outcomes such as response to ovarian stimulation, time to pregnancy, and age at natural menopause. [16] [17] [18] In young women with cancer, biomarkers of ovarian reserve have been followed longitudinally as surrogate measures of ovarian function. The pattern of change from pretreatment through the first 12 to 24 months posttreatment has been described and replicated in small cohorts. [19] [20] [21] Using AMH as an example, levels fall with exposure to gonadotoxic therapy; for some, AMH levels rise posttreatment, suggesting ovarian recovery. The pattern of change in FSH levels has been observed to be inverse to that of AMH. 22, 23 There is significant intra-and interindividual variability in the pattern of change in ovarian reserve measures longitudinally. There are two clinical implications of the data on ovarian reserve measurements in cancer survivors. First, for many survivors, the rise of AMH, fall of FSH, and resumption of regular menses after completion of gonadotoxic cancer treatment support the concept of a residual window of ovarian function and fertility, which represents an opportunity to conceive. Unfortunately, data are lacking on when ovarian recovery plateaus and subsequent decline begins. In addition, young cancer survivors seek to achieve social milestones including partnered relationships and cancer milestones such as longer duration of cancer survivorship prior to pregnancy attempt. 24 However, these milestones take time to achieve and compete with earlier loss of fertility. Hence, fertility counseling on the residual window of ovarian function should help survivors recognize the importance of not delaying pregnancy and a potential second opportunity to undergo fertility preservation via oocyte or embryo banking in this posttreatment period. Second, if ovarian reserve biomarkers are to be measured posttreatment, providers and survivors need to be aware the Note: À, evidence suggests no effect; þ, evidence suggests adverse effect; ?, unknown effect limitations of these measurements. There is a lack of studies in this population on the ability of ovarian reserve biomarkers to predict clinically relevant fertility outcomes like fecundability. Ovarian reserve biomarkers can have significant fluctuations posttreatment. If they are to be measured, serial samples, rather than a single measurement, to track an individual's trajectory over time are likely to be more helpful. Take-home message: Survivors should be counseled that their fertility and likelihood of having births after cancer are lower, but most will have a residual window of ovarian function and fertility after primary cancer treatment. As data estimating the remaining fertility window are lacking, survivors after cancer treatment should consider attempting pregnancy earlier or explore another opportunity for oocyte or embryo banking.
Contraception
Reproductive-aged cancer survivors have complex contraception considerations. Effective methods of contraception need to be used during exposure to teratogenic cancer treatments, and cancer type and comorbidities must be considered while choosing contraceptive method. The American Congress of Obstetricians and Gynecologists recommends that all sexually active women of reproductive age be thoroughly educated on the risks of conceiving during cancer therapy and encouraged to use effective contraception during treatment. 25 Further, the National Comprehensive Cancer Network Practice Guidelines for Adolescent and Young Adult Oncology include discussion of contraceptive options prior to the initiation of cancer therapy.
26
A consequence of inadequate contraception is unintended pregnancy and pregnancy termination. There are no largescale data on the rate of unintended pregnancy. Several retrospective cohort studies have described induced abortion in cancer survivors. [27] [28] [29] [30] [31] [32] 
Contraception Utilization Rates Are Low in Reproductive-Aged Cancer Survivors
In the United States, the rate of contraception in the general population of reproductive-aged women (ages 14-44) is ascertained through the National Survey for Family Growth conducted by the Centers for Disease Control and Prevention (CDC). 34 In the 2011-2013 cycle, 62% of reproductive-aged U.S.
women reported current contraceptive use. 35 Excluding women who were not at risk of unintended pregnancy, such as those who were not sexually active (19%) or pregnant, postpartum, or seeking pregnancy (9.5%), 87% of the remaining women reported contraception use. Among women reporting contraception use, the majority (78%) reported using highly effective methods, or World Health Organization (WHO) Tiers I or II methods including surgical sterilization, contraceptive implant, intrauterine device (IUD), combined hormonal contraceptive (CHC), injectable progestin, or progestin only pill.
36
Several observational studies have demonstrated suboptimal rates of contraception among reproductive-aged cancer survivors. A cross-sectional study of 107 female cancer survivors at a single comprehensive cancer center reported 76% of participants using contraception during primary cancer treatment. 37 Among the subset of 71 who were sexually active after cancer diagnosis, only 27% selected highly effective methods (WHO Tiers I or II). 37 A second study recruited survivors from the California Cancer Registry (CCR). Among 918 nongynecologic cancer survivors who resumed regular menstruation after cancer therapy and had no history of surgical sterilization, 47% reported any contraceptive use, with only 33% of contracepting respondents reporting use of highly effective WHO Tiers I or II methods.
38
Compared with the general U.S. population of reproductive-aged women, the rates of contraception and use of highly effective methods are lower. The Fertility Information Research Study recruited 289 survivors from cancer advocacy and fertility preservation programs across the United States. Following age-adjustment to compare survivors to the general population, 69% of the general population used a method of contraception, compared with only 57% of survivors (p < 0.01). 39 Moreover, 53% of the general population reported use of Tiers I or II methods, while only 34% survivors reported use of these highly effective contraceptive methods (p < 0.01).
39
Family planning counseling in female cancer survivors is associated with higher rates of effective contraception. Qualitative studies of female reproductive-aged cancer survivors consistently report a desire for counseling on contraceptive options and the likelihood of becoming pregnant following cancer therapy. 40, 41 Contraceptive counseling by a health care provider prior to cancer treatment was reported by 65% of sexually active female cancer survivors at a single comprehensive cancer center in the United States. 37 Among survivors who were on average 2.4 years since their cancer diagnosis, 65% reported family planning counseling within the prior 12 months. 39 In both studies, women who reported receiving contraceptive counseling were more likely to use Tier I or II method. The specific discussion on contraception is important, as a survey of California cancer survivors demonstrated no association between fertility discussions prior to cancer treatment and the survivors' contraception practices after treatment.
38

Consideration of Cancer Type and Comorbidities in Contraceptive Counseling
To provide appropriate counseling on contraceptive options for women after cancer diagnosis and therapy, careful 
42
Cancer type and choice of contraceptive methods: There are few medical restrictions for use of barrier contraceptives and IUDs in cancer patients. The exception is the cervical cap, which is contraindicated in untreated cervical cancer. Initiation of IUD use is also contraindicated in endometrial and cervical cancers, but IUDs may be continued in patients who subsequently receive new cancer diagnoses.
On hormonal contraceptives, the MEC cautions against progestin containing and CHC in women with history of breast cancer. Thus, nonhormonal methods of contraception such as the copper IUD may be considered first-line methods for breast cancer patients. 43 Several reports have shown that neither movement nor clinically significant heating was associated with the copper IUD when undergoing magnetic resonance imaging using equipment <3.0T. 44 While the MEC cautions against use of the levonorgestrel IUD (LNG IUD) in women with a history of breast cancer, several studies have assessed its efficacy in preventing endometrial polyps, hyperplasia, and cancer in breast cancer survivors taking tamoxifen. A Cochrane review of LNG IUD use among women with breast cancer on tamoxifen suggested that the method decreased the incidence of benign endometrial polyps, but available trials were too small to study prevention of hyperplasia, endometrial cancer, and breast cancer recurrence.
45
Thromboembolic risk: Caution is recommended on CHC use in patients diagnosed with venous thromboembolic disease (VTE) in the setting of ongoing cancer diagnoses or treatment. In patients with active cancer from diagnosis through 6 months of clinical remission, the CDC and World Health Organization (WHO) both recommend against CHC use in patients with history of VTE, active VTE, or VTE with established anticoagulant therapy for at least 3 months. Exceptions may be considered, however, in cases where CHCs are used in a therapeutic capacity to decrease risk of hemorrhagic ovarian cysts and severe menorrhagia in patients receiving therapeutic anticoagulation.
42 When avoiding CHCs due to risk of recurrent VTE, barrier methods and IUDs are acceptable alternatives.
Bone loss: Chronic corticosteroid use and certain chemotherapies have been shown to decrease bone density. Given that depot medroxyprogesterone acetate and the etonogestrel contraceptive implant have been associated with decreased bone mineral density, it has been recommended that these methods be avoided in women who develop osteopenia or osteoporosis following cancer therapy.
43
Take-home message: A limited number of observational studies have identified a gap in care in the contraceptive practices of reproductive-aged cancer survivors. Clinically significant proportions of survivors at risk of unintended pregnancy are not contracepting or using the most effective methods of contraception. Providers need to be aware of MEC and professional society guidelines when counseling this population. While contraception-specific counseling may improve contraceptive practices, further research is needed on how to deliver the most effective contraceptive counseling, when to deliver this information, and what are patientimportant factors in contraceptive decision making.
Maternal and Offspring Health
Reproductive-aged cancer survivors frequently have significant concerns about their personal and offspring health when considering starting a family. These reproductive concerns are associated with depressive symptoms and worse quality of life;
46 for some survivors, these concerns result in choosing to avoid pregnancy. 47 Primary care providers, including obstetrician gynecologists, oncology providers, and fertility and maternal fetal medicine specialists, serve as an important source of information on maternal and offspring health for survivors. In this section, we discuss risks of spontaneous abortion (SAB), preterm birth, cardiovascular diseases, and gestational diabetes in reproductive-aged survivors attempting pregnancy, summarized in ►Table 4. We also include breastfeeding considerations. 
Spontaneous Abortion
31
While the overall risk of SAB does not appear increased, cranial radiation is associated with higher SAB rates. In the Childhood Cancer Survivor Study, compared with those with no radiation therapy, women exposed to cranial and spinal radiation or cranial radiation alone had a 1.4-to 2.2-fold higher SAB rate; spinal radiation alone did not appear to increase risk.
32 By gestational age, cranial and spinal radiation was associated with significantly increased SAB risk occurring !12 weeks of gestation (RR: 6.1, 95% CI: 3.06-12.2), but no increased risk was seen in SAB less than 12 weeks of gestation. 32 The Danish registry study demonstrated almost a two-fold increased SAB risk (PR: 1.8, 95% CI: 1.1-3.0) in survivors who received highdose radiation treatment to the pituitary gland.
28
Abdominal and pelvic radiation is also associated with higher SAB risk. In the British Childhood Cancer Survivor Study, abdominal radiotherapy was associated with a modest increase in SAB (odds ratio [OR] 1.4, 95% CI: 1.0-1.9), largely This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
attributable to more SAB beyond 12 weeks of gestation (OR: 1.9, 95% CI: 1.1-3.2) rather than SAB less than 12 weeks (OR: 1.0, 95% CI: 0.7-1.5). 33 In the Danish population, survivors exposed to high-dose radiation to the ovary and uterus had an almost three-fold increased risk of SAB (PR: 2.8, 95% CI: 1.7-4.7) versus their sisters. 28 Radiotherapy in which ovaries were in or near the field may be associated with higher risk of SAB (radiation field RR: 1.9, 95% CI: 0.8-4.2; near radiation field RR: 1.6, 95% CI: 0.95-2.8), while SAB risk did not appear increased if ovaries were shielded (RR: 0.9, 95% CI: 0.2-3.5). 32 In contrast to the other studies, the Canadian cohort showed that abdominal-pelvic radiation was not related to SAB risk, but this cohort was significantly smaller, limiting power.
49
Similar to women without a history of cancer, smoking appears to increase the SAB rate in this population. SAB risk in smokers appeared augmented with uterine radiation exposures. Survivors with more than 5 pack-years of smoking history had higher risk for SAB among those with > 2.5 Gy uterine radiation (OR: 53.9; 95% CI: 2.2-1326.1) than those with 2.5 Gy of uterine radiation (OR: 1.9; 95% CI: 1.2-3.0; P interaction ¼ 0.01).
50
There is considerable evidence that radiation to the brain, abdomen, or pelvis increases SAB risk to 1.5-to 3-fold, for which survivors need to be counseled. Outside of these exposures, SAB rates did not appear to differ by cancer type or chemotherapy exposure, including alkylating chemotherapy exposure. 32 The mechanisms by which radiation increases miscarriage risk are hypothesized to include direct radiation damage to (1) endometrium causing atrophic changes; (2) myometrium causing fibrosis, decreased elasticity of the muscle; and (3) uterine vessels disruption.
51,52
More studies are needed to delineate causes of higher rates of loss in the second trimester to develop interventions or better assessments of the uterus prior to conception. Take-home message: Radiation exposure to the brain, abdomen, or pelvis increases SAB risk to 1.5-to 3-fold. Otherwise, miscarriage rates do not appear to be different by cancer type or chemotherapy exposure.
Preterm Birth, Low Birth Weight, and Small for Gestational Age
Preterm birth prior to 37 weeks of gestation poses significant risks to maternal and offspring health. Several large retrospective cohort studies evaluated premature birth among childhood cancer survivors. Compared with siblings and/or the general population, higher rates of preterm birth are observed in cancer survivors. With increased rates of preterm birth, survivors are also at higher risk of delivering low-birth-weight (LBW) offspring. 32, 54, 56, 58 Absolute risks of LBW varied from 7 to 15%. 49, [54] [55] [56] 59 The Childhood Cancer Survivor Study reported a two-fold increased risk of having an offspring less than 2,500 g compared with siblings (RR: 2.1, 95% CI: 1.4-3.0). Consistently, a two-to three-fold increased risk of LBW offspring was observed in cancer survivors compared with controls. 33, 48, 54, 56, 57 Importantly, offspring of survivors do not appear to be at greater risk of being small for gestational age (SGA), indicating that the risk of LBW is attributable to preterm delivery rather than growth restriction.
54,56,59
Abdominal radiation is strongly associated with a two-to three-fold increase in preterm birth risk. Wilms' tumor survivors historically have undergone significant abdominal radiation. The National Wilms Tumor Study reported 10% risk of prematurity in patients with no prior radiation, compared with 22% in patients exposed to more than 25 Gy of abdominal radiation (p ¼ 0.001); among whole abdominal irradiation patients, 33% of infants were born prematurely. 55 The
Childhood Cancer Survivor Study and the British Childhood Cancer Survivor Study reported 29 to 41% preterm birth rate in Wilms' tumor survivors, compared with 9 to 28% in other cancer types. 32, 33 Uterine radiation exposure led to increased prematurity risk in dose-dependent fashion. Importantly, the risks of preterm birth in females who have undergone abdominal radiation did not appear to differ by whether radiation exposure occurred prior to or following menarche.
56
While the risk for SGA was not higher in the overall cancer survivor population compared with controls, some evidence suggests that abdominal and/or pelvic radiation increases the risk of not only LBW but also SGA. Across cohorts, abdominal or pelvic radiation increased the risk of LBW offspring to two-to four-fold. 32, 33, 49, [58] [59] [60] Within the Childhood Cancer Survivor Study cohort, radiation exposure of greater than 5 Gy to the uterus was shown to be associated with increased risk of SGA (>5 Gy 18% SGA vs. no radiation 7.8%, p ¼ 0.003). 56 Ovarian radiation, pituitary radiation, and alkylator chemotherapy were not associated with SGA.
While the bulk of data on preterm birth focuses on Wilms' tumor, most observational studies including the Childhood Cancer Survivor Study and the British Childhood Cancer Survivor Study have reported generally no association between preterm births and other common cancer types or exposure to alkylating chemotherapy. 33, 56 The exception is the SEER registry linkage study, in which leukemia (RR: 2.6, 95% CI: 1.8-3.6), lymphoma (RR: 1.8, 95% CI: 1.3-2.5), and bone cancers (RR: 2.2, 95% CI: 1.2-3.9) were associated with preterm birth.
54
The pathophysiology of preterm birth in cancer survivors is not understood, as patient report and registry linkage studies do not ascertain spontaneous versus induced preterm deliveries. As well, to our knowledge, no interventional studies on preterm birth have been performed in this highrisk population. Further research to delineate causes of preterm birth and test interventions on these causes are needed.
Take-home message: Higher rates of preterm birth and LBW neonates are observed among female adolescent and young adult cancer survivors, particularly in those exposed to abdominal/pelvic radiation (two-to three-fold increased risks). Abdominal or pelvic radiation also increases the risk of offspring being small for gestational age.
Labor and Delivery Considerations
Cesarean delivery: Three cohorts of cancer survivors demonstrate increased cesarean deliveries in female cancer survivors. Survivors from a single Norwegian comprehensive cancer center had a 23% cesarean delivery rate, compared with 8% in controls (OR: 2.3, 95% CI: 1.9-2.7).
48 These estimates were similar in magnitude to the cohort from Western Australia. 53 U.S. data showed a more modest difference, with 22% cesarean delivery rate in cancer survivors and 17% in controls (RR: 1.2, 95% CI: 0.99-1.3). Cancer treatments did not appear to be associated with this outcome.
54
Risks specific to abdominal radiation: In a small cohort of 40 Dutch childhood cancer survivors followed at a single center, increased risks of postpartum hemorrhage (>1 L blood loss within 24 hours after delivery) was observed in two of six survivors with abdominal radiation exposure, compared with 5% of controls without history of cancer (p ¼ 0.007). 61 This complication may be related to need for manual placenta extraction (17% in patients exposed to abdominal radiation compared with 3% controls, p ¼ 0.08). 61 This finding has not been replicated. In Wilms'
tumor survivors, fetal malposition, premature rupture of membranes, and obstructed labor did not occur more frequently with increased radiation dose.
55
Take-home message: Female childhood cancer survivors are at increased risk of cesarean delivery.
Breastfeeding
Reproductive-aged cancer survivors may face breastfeeding challenges from central nervous system or chest radiation. A small series reported failure to lactate after delivery in 10 of 12 females exposed to 24-Gy cranial radiotherapy as CNS prophylaxis for acute lymphoblastic leukemia (ALL), despite normal breast development and regular menstruations prior to conception.
62 Lower CNS radiation doses may not interfere with breastfeeding; a further series of five ALL survivors at the same institution who were treated with 18-Gy CNS radiation reported normal lactation in all participants. 62 An additional risk to lactation is chest radiation. In a retrospective cohort study, Hodgkin's lymphoma survivors exposed to chest radiation were less successful at breastfeeding attempts compared with healthy controls (61 vs. 79%, respectively, p ¼ 0.04).
63
Discussion of these challenges with these survivors is important to managing expectations of breastfeeding. Take-home message: Childhood cancer survivors who underwent CNS or chest radiation might experience more problems with breastfeeding compared to healthy controls.
Cardiovascular Concerns
Cancer treatments pose a myriad of cardiovascular risks that can impact maternal health (►Table 5). According to the Children's Oncology Group Long-Term Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers (COG LTFU Guidelines), survivors exposed to anthracycline antibiotics or chest radiation are recommended to have screening with echocardiography and electrocardiography at entry into long-term follow-up and then periodically based on clinical indication, age at treatment, radiation dose, and cumulative anthracycline dose. 64 While hypertension has been reported to be higher following flank radiation in Wilms' tumor survivors (12% nonradiated vs. 24% in radiated), 55 risks of preeclampsia do not appear significantly higher in several cohort studies. 53, 54, 61 In the SEER Registry linkage study, preeclampsia was reported in 5% of birth records of cancer survivors, compared with 4% of the general population (RR: 1.0, 95%: CI 0.7-1.4). A modestly higher risk was reported in the Western Australia cohort (4% of survivors vs. 3% of controls, adjusted RR: 1.4 [95% CI: 1.1-1.9]).
53
Pregnancy-associated cardiomyopathy poses a life-threatening risk. In a select population of reproductive-aged cancer survivors, risk is highest in survivors exposed to anthracyclines, but the absolute risk is low. For example, in a large retrospective cohort study of 847 survivors with 1,554 pregnancies, pregnancy-associated cardiomyopathy in survivors was low (0.3%). Survivors who developed cardiomyopathy had higher anthracycline exposure compared with those who did not (321 vs. 164 mg/m 2 , p < 0.01).
65
There are additional cardiopulmonary risks following some cancer therapies that require consideration prior to pregnancy. According to the COG LTFU Guidelines, cardiology evaluation is recommended for women exposed to anthracyclines (!300 mg/m 2 based on doxorubicin) or any chest radiation who are pregnant or prior to pregnancy. 64 Evaluation should include ECHO before pregnancy, periodically during pregnancy (especially during the third trimester), and cardiac monitoring during labor and delivery due to risk of cardiac failure. As new targeted therapy is increasingly used and many incur cardiovascular risks, long-term toxicity and its impact on maternal health during pregnancy need to be studied. Take-home message: Female cancer survivors with history of anthracycline and/or chest radiation exposures are at increased risk for developing pregnancy-associated cardiomyopathy. While the absolute risk of this complication is low, the clinical consequence is catastrophic. Preconception cardiac evaluations are recommended for survivors who are at risk.
Gestational Diabetes
There are limited and inconsistent data on whether gestational diabetes mellitus (GDM) risk is increased in cancer survivors. The absolute rates are low. In the Western Australia cohort, 5% of survivors were diagnosed with GDM, compared with 2% of controls (adjusted RR: 2.7, 95% CI: 2.1-3.6). 53 In the SEER Registry linkage study, the rate of diabetes was 1.6%, compared with 1.4% in controls (RR: 1.0, 95% CI: 0.5-2.0). 54 There are no large-scale data on what cancer types and treatments are related to GDM in cancer survivors. Take-home message: Limited and inconsistent data exist on risk of GDM among female childhood cancer survivors. Several studies demonstrated trend toward increased risk.
Stillbirth
Stillbirth, or the death of a fetus after the 20th week of pregnancy, is a devastating pregnancy outcome. Several large retrospective cohort studies from the United States, Denmark, Canada, Norway, and the United Kingdom have reported stillbirth risks among female childhood cancer survivors and compared them to risks in siblings and/or the general population. 28, 32, 33, 48, 49, 60, 66, 67 The absolute risks of stillbirths were low. In the Childhood Cancer Survivor Study, 37 stillbirths occurred in 4,029 pregnancies (0.9%). Survivors did not have higher rates of stillbirth compared Take-home message: Stillbirth risk is not increased among childhood cancer survivors, except for patients exposed to abdominal and/or pelvic radiation.
Childhood Cancer Risk in Offspring
Reproductive-aged cancer survivors express concern about cancer risk in their offspring. 68 Several large cohort studies in 
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Of note, discovery of cancer gene risk mutations continues to evolve. Hereditary cancer screening is rapidly expanding beyond traditional BRCA and microsatellite instability testing. As clinical practice evolves, genetic risk assessment (or reassessment) may be indicated in reproductive-aged cancer survivors, as carrier status of a risk mutation would impact both personal health and offspring health risk.
Take-home message: No increased risk of childhood cancer has been observed in children of cancer survivors, with the exception of hereditary cancers.
Birth Defects and Chromosomal Abnormalities
Following exposure to cancer therapies, survivors also report concern about risks of major birth defects and chromosomal abnormalities in their offspring. A number of large cohort studies have reported on birth defect and chromosomal abnormalities in cancer survivors and compared them to the general population or siblings. 27, 49, 54, 57, 58, 60, 61, 66, 70, [72] [73] [74] [75] [76] Across studies, congenital malformation rates vary between 3 and 5% in survivors, while rates of abnormal karyotypes were even lower (0.2-0.5%). 67, 73, 74 Most cohorts showed no higher rates of birth defects in survivors compared with controls. For example, the Danish Cancer Registry demonstrated 2.6% of offspring of cancer survivors exposed to radiation treatment had birth defects versus 2.3% of offspring of the general population (PR: 1.1, 95% CI: 0.8-1.5). 75 In addition, trisomy 21 (RR: 1.1, 95% CI: 0.2-5.5) and Turner's syndrome (RR: 1.3, 95% CI: 0.2-8.0) risks were not higher in offspring of cancer survivors than in sibling controls or the general population.
73
Birth defects and chromosomal abnormalities were also not related to cancer treatments.
49,73,74
Take-home message: Overall, rates of birth defects among childhood cancer survivors are low, do not appear increased comparing to general population, and are not higher in patients exposed to flank/abdominal/pelvic radiation.
Conclusion
The majority of female cancer patients diagnosed at a young age will become long-term survivors and face reproductive health risks related to their cancer treatments. These risks include infertility, inadequate contraception, pregnancy complications and impact on health of their offspring. These risks differ by cancer treatments. Family planning counseling is important in this population to discuss both future fertility and effective contraception. Preconception counseling is critical to evaluate and attempt to modify pregnancy-related risks. Equally important to informing survivors of their increased reproductive risks is counseling on which risks they do not face. Currently, this clinical care benefits from the expertise of both reproductive and oncology specialists, aided by professional guidelines including the U.S. MEC, COG LTFU Guidelines, National Comprehensive Cancer Network Guidelines for Survivorship, and relevant American Society of Clinical Oncology guidelines. Many clinically important questions remain unanswered, from generating perinatal risk estimates by cancer treatment exposures to predicting the window of fertility after cancer. As well, health services research on effective strategies to disseminate information on these modifiable risks to survivors and their health care providers is needed.
